MELVILLE, NY, July 19, 2013 -(eTeligis via ACCESSWIRE)- Bovie Medical Corporation (the "Company") (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced that Royce T. Adkins, M.D., a key opinion leader in Women's Health and regularly listed as one of "America's Top Obstetricians and Gynecologists" by Who's Who Best Doctors in America, addressed Bovie's Annual Meeting held on July 16, 2013 at 3:00 P.M. Dr. Adkins shared his and other surgeons' sentiments and conclusions on J-Plasma(R).
Dr. Adkins stated, "In 25 years as a surgeon, I have not previously had the ability to use such a safe product that not only gives me precise tissue dissection with the ability to coagulate safely near delicate tissues and other vital structures. Multiple colleagues have duplicated my experience and often say, 'Why didn't I think of this?' Often in surgery, surgeons may have the opportunity to utilize new and revolutionary tools. Unfortunately, the majority of these innovations frequently come with the significant disadvantage of adding cost to an already overwhelmed healthcare system. Compared to many of the tools surgeons previously have utilized, J-Plasma(R) outperforms many while providing an actual cost savings of several magnitudes to healthcare delivery systems who increasingly have either fixed or lower reimbursement for the majority of the care they provide our patients."
He concluded, "The unique physical qualities of a helium based gas plasma, used in J-Plasma(R), may now possibly give us even better results in multiple applications due to the 'cooling effect' specifically on the tissue itself when compared to the heat produced by conventional electrosurgery and laser technology. In other words, a cool drink of water will basically not lead to the same degree of potential thermal tissue damage as compared to a boiling cup of coffee!"
Results of shareholder voting can be found in the Company's 8-K filing of July 17, 2013.
Cautionary Note on Forward-Looking Statements
Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Form 10‑K for the year ended December 31, 2012. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie's website www.boviemed.com.
For further information contact:
Bovie Medical Investor Relations and Shareholder Information
Joseph M. Vazquez III
Phone: (800) 448-7097
SOURCE: Bovie Medical Corporation